Stocks on the move
Real-time equity news
U.S. stock market report
1728 ET 01Apr2010
Economic diary for April 2
Friday's economic diary features the release of the government's March non-farm payrolls report at 8:30 a.m. (1230 GMT)
For more please double click
Reuters Messaging rm://ellis.mnyandu.reuters.com@reuters.net
1721 ET 01Apr2010
Dow, S&P 500 ride data higher; RIM drags Nasdaq
The Dow and the S&P 500 rose on Thursday, thanks to upbeat economic data, but the Nasdaq was stagnant as investors pummeled shares of Research In Motion following downbeat results.
Anxiety about Friday's March payrolls report held gains in check. The U.S. stock market will be closed for Good Friday when the March unemployment report is released, and some investors opted to book profits before the long Easter weekend, derailing an earlier 1 percent run-up.
For more please double click
Reuters Messaging rm://ellis.mnyandu.reuters.com@reuters.net
1527 ET 01April2010-U.S. data boosts self
sustaining recovery hopes
The number of U.S. workers filing new claims for jobless aid fell last week and factory activity in March hit its highest level in more than 5-1/2 years, strengthening hopes for a self-sustaining recovery.
The data on Thursday came a day before the release of the government's closely watched employment report for March. It is expected to show nonfarm payrolls grew for only the second time since the economy fell into recession in December 2007.
For more please double click
Reuters Messaging: caroline.valetkevitch.reuters.com@reuters.net
1426 ET 01April2010
Allos Therapeutics options volume swells
At least one options trader was betting on a big rally for Allos Therapeutics, said optionMonster analyst David Russel in comments on the Web site. A purchase of 5,000 July $10 calls for $0.50 and the sale of a matching number of July $5 puts for $0.20 was detected, Russel said. The trade cost a net debit of $0.30, and volume was more than twice open interest in both strikes, he said. The stock was currently trading 2.2 percent higher at $7.60. The bullish combination strategy in options is designed to leverage a rally in the shares. The investor will double his or her money for every $0.30 that the stock closes above $10.30 on expiration, he said.
Reuters Messaging: angela.moon.reuters.com@reuters.net
1408 ET 01April2010
Ford attracts bullish call options activity
Ford Motor's shares recovered a portion of the previous session's steep decline after the automaker said its sales in China surged 84 percent in the first quarter. Ford's shares are up 1.3 percent at $12.73. In the options market, one bullish options player employed the use of a debit call spread in the May contract in order to position for continued share price appreciation through expiration, according to Caitlin Duffy, options analyst at Interactive Brokers Group. The investor purchased 10,000 calls at the May $14 strike for an average premium of 38 cents apiece and sold the same number of calls at the higher May $16 strike for 8 cents each, she said. Net premium paid for the spread amounts to $0.30 per contract. The trader stands ready to accumulate maximum potential profits of $1.70 per contract, for total gains of $1.7 million, should Ford's share price jump more than 24.3 percent from the current price to surpass $16.00 ahead of expiration day in May, Caitlin said. Options investors exchanged more than 132,800 contracts on the automaker in the first half of the trading day, and displayed a preference for calls by trading more than 2 call options for each single put contract in play thus far in the session.
Reuters Messaging: angela.moon.reuters.com@reuters.net
1144 ET 01April2010
Court upholds patent on Lilly's Gemzar drug
An Indiana federal court upheld the main patent on Eli Lilly and Co's Gemzar cancer drug, protecting the blockbuster product's U.S. marketing exclusivity through Nov. 15, the company said on Thursday.
Industry analysts have predicted the drug, which had global sales of $1.36 billion in 2009, will face generic competition in the important U.S. market by November, when its main patent lapses. The medicine is used to treat ovarian, lung, breast and pancreatic cancer.
For details, see
Shares of Lilly slid 0.1 percent to $36.20.
Reuters Messaging: ryan.vlastelica.reuters.com@reuters.net Keywords: MARKETS STOCKSNEWS
COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Real-time equity news
U.S. stock market report
1728 ET 01Apr2010
Economic diary for April 2
Friday's economic diary features the release of the government's March non-farm payrolls report at 8:30 a.m. (1230 GMT)
For more please double click
Reuters Messaging rm://ellis.mnyandu.reuters.com@reuters.net
1721 ET 01Apr2010
Dow, S&P 500 ride data higher; RIM drags Nasdaq
The Dow and the S&P 500 rose on Thursday, thanks to upbeat economic data, but the Nasdaq was stagnant as investors pummeled shares of Research In Motion following downbeat results.
Anxiety about Friday's March payrolls report held gains in check. The U.S. stock market will be closed for Good Friday when the March unemployment report is released, and some investors opted to book profits before the long Easter weekend, derailing an earlier 1 percent run-up.
For more please double click
Reuters Messaging rm://ellis.mnyandu.reuters.com@reuters.net
1527 ET 01April2010-U.S. data boosts self
sustaining recovery hopes
The number of U.S. workers filing new claims for jobless aid fell last week and factory activity in March hit its highest level in more than 5-1/2 years, strengthening hopes for a self-sustaining recovery.
The data on Thursday came a day before the release of the government's closely watched employment report for March. It is expected to show nonfarm payrolls grew for only the second time since the economy fell into recession in December 2007.
For more please double click
Reuters Messaging: caroline.valetkevitch.reuters.com@reuters.net
1426 ET 01April2010
Allos Therapeutics options volume swells
At least one options trader was betting on a big rally for Allos Therapeutics, said optionMonster analyst David Russel in comments on the Web site. A purchase of 5,000 July $10 calls for $0.50 and the sale of a matching number of July $5 puts for $0.20 was detected, Russel said. The trade cost a net debit of $0.30, and volume was more than twice open interest in both strikes, he said. The stock was currently trading 2.2 percent higher at $7.60. The bullish combination strategy in options is designed to leverage a rally in the shares. The investor will double his or her money for every $0.30 that the stock closes above $10.30 on expiration, he said.
Reuters Messaging: angela.moon.reuters.com@reuters.net
1408 ET 01April2010
Ford attracts bullish call options activity
Ford Motor's shares recovered a portion of the previous session's steep decline after the automaker said its sales in China surged 84 percent in the first quarter. Ford's shares are up 1.3 percent at $12.73. In the options market, one bullish options player employed the use of a debit call spread in the May contract in order to position for continued share price appreciation through expiration, according to Caitlin Duffy, options analyst at Interactive Brokers Group. The investor purchased 10,000 calls at the May $14 strike for an average premium of 38 cents apiece and sold the same number of calls at the higher May $16 strike for 8 cents each, she said. Net premium paid for the spread amounts to $0.30 per contract. The trader stands ready to accumulate maximum potential profits of $1.70 per contract, for total gains of $1.7 million, should Ford's share price jump more than 24.3 percent from the current price to surpass $16.00 ahead of expiration day in May, Caitlin said. Options investors exchanged more than 132,800 contracts on the automaker in the first half of the trading day, and displayed a preference for calls by trading more than 2 call options for each single put contract in play thus far in the session.
Reuters Messaging: angela.moon.reuters.com@reuters.net
1144 ET 01April2010
Court upholds patent on Lilly's Gemzar drug
An Indiana federal court upheld the main patent on Eli Lilly and Co's Gemzar cancer drug, protecting the blockbuster product's U.S. marketing exclusivity through Nov. 15, the company said on Thursday.
Industry analysts have predicted the drug, which had global sales of $1.36 billion in 2009, will face generic competition in the important U.S. market by November, when its main patent lapses. The medicine is used to treat ovarian, lung, breast and pancreatic cancer.
For details, see
Shares of Lilly slid 0.1 percent to $36.20.
Reuters Messaging: ryan.vlastelica.reuters.com@reuters.net Keywords: MARKETS STOCKSNEWS
COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.